{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1363670319015430144.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.jaut.2015.06.005"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0896841115000876?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0896841115000876?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"26162757"}},{"identifier":{"@type":"HANDLE","@value":"11380/1079761"}},{"identifier":{"@type":"HANDLE","@value":"11585/590951"}}],"dc:title":[{"@value":"Efficacy of anti-TNF alpha in severe and/or refractory Behçet's disease: Multicenter study of 124 patients"}],"description":[{"notation":[{"@value":"To report the efficacy and safety of anti-TNF agents in patients with severe and/or refractory manifestations of Behçet's disease (BD).We performed a multicenter study of main characteristics and outcomes of anti-TNF alpha treatments [mainly infliximab (62%), and adalimumab (30%)] in 124 BD patients [48% of men; median age of 33.5 (28-40) years].Overall response (i.e. complete and partial) rate was 90.4%. Clinical responses were observed in 96.3%, 88%, 70%, 77.8%, 92.3% and 66.7% of patients with severe and/or refractory ocular, mucocutaneous, joint, gastro-intestinal manifestations, central nervous system manifestations and cardiovascular manifestations, respectively. No significant difference was found with respect to the efficacy of anti-TNF used as monotherapy or in association with an immunosuppressive agent. The incidence of BD flares/patient/year was significantly lower during anti-TNF treatment (0.2 ± 0.5 vs 1.7 ± 2.4 before the use of anti-TNF, p  0.0001). The prednisone dose was significantly reduced at 6 and 12 months (p  0.0001). In multivariate analysis, retinal vasculitis was negatively associated with complete response to anti-TNF (OR = 0.33 [0.12-0.89]; p = 0.03). The efficacy and relapse free survival were similar regardless of the type of anti-TNF agent used. After a median follow-up of 21 [7-36] months, side effects were reported in 28% of patients, including infections (16.3%) and hypersensitivity reactions (4.1%). Serious adverse events were reported in 13% of cases.Anti-TNF alpha therapy is efficient in all severe and refractory BD manifestations. Efficacy appears to be similar regardless of the anti-TNF agent used (infliximab or adalimumab)."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1380285706291303043","@type":"Researcher","foaf:name":[{"@value":"H. Vallet"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430016","@type":"Researcher","foaf:name":[{"@value":"S. Riviere"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430148","@type":"Researcher","foaf:name":[{"@value":"A. Sanna"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430155","@type":"Researcher","foaf:name":[{"@value":"A. Deroux"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430150","@type":"Researcher","foaf:name":[{"@value":"G. Moulis"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430017","@type":"Researcher","foaf:name":[{"@value":"O. Addimanda"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430273","@type":"Researcher","foaf:name":[{"@value":"C. Salvarani"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430278","@type":"Researcher","foaf:name":[{"@value":"M. Lambert"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430152","@type":"Researcher","foaf:name":[{"@value":"P. Bielefeld"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430020","@type":"Researcher","foaf:name":[{"@value":"P. Seve"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430018","@type":"Researcher","foaf:name":[{"@value":"J. Sibilia"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430402","@type":"Researcher","foaf:name":[{"@value":"Jl Pasquali"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430153","@type":"Researcher","foaf:name":[{"@value":"Jb Fraison"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430149","@type":"Researcher","foaf:name":[{"@value":"I. Marie"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430276","@type":"Researcher","foaf:name":[{"@value":"L. Perard"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430279","@type":"Researcher","foaf:name":[{"@value":"L. Bouillet"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430151","@type":"Researcher","foaf:name":[{"@value":"F. Cohen"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430145","@type":"Researcher","foaf:name":[{"@value":"D. Sene"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430019","@type":"Researcher","foaf:name":[{"@value":"Y. Schoindre"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430277","@type":"Researcher","foaf:name":[{"@value":"O. Lidove"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430147","@type":"Researcher","foaf:name":[{"@value":"P. Le Hoang"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430274","@type":"Researcher","foaf:name":[{"@value":"E. Hachulla"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430401","@type":"Researcher","foaf:name":[{"@value":"O. Fain"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430146","@type":"Researcher","foaf:name":[{"@value":"X. Mariette"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430156","@type":"Researcher","foaf:name":[{"@value":"T. Papo"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430400","@type":"Researcher","foaf:name":[{"@value":"B. Wechsler"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430144","@type":"Researcher","foaf:name":[{"@value":"B. Bodaghi"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430021","@type":"Researcher","foaf:name":[{"@value":"M.Resche Rigon"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430272","@type":"Researcher","foaf:name":[{"@value":"P. Cacoub"}]},{"@id":"https://cir.nii.ac.jp/crid/1383670319015430275","@type":"Researcher","foaf:name":[{"@value":"D. Saadoun"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"08968411"}],"prism:publicationName":[{"@value":"Journal of Autoimmunity"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2015-08","prism:volume":"62","prism:startingPage":"67","prism:endingPage":"74"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0896841115000876?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0896841115000876?httpAccept=text/plain"}],"createdAt":"2015-07-08","modifiedAt":"2025-10-12","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Adult","dc:title":"Adult"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Tumor%20Necrosis%20Factor-alpha","dc:title":"Tumor Necrosis Factor-alpha"},{"@id":"https://cir.nii.ac.jp/all?q=Behcet%20Syndrome","dc:title":"Behcet Syndrome"},{"@id":"https://cir.nii.ac.jp/all?q=Antibodies,%20Monoclonal","dc:title":"Antibodies, Monoclonal"},{"@id":"https://cir.nii.ac.jp/all?q=Severity%20of%20Illness%20Index","dc:title":"Severity of Illness Index"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Recurrence","dc:title":"Recurrence"},{"@id":"https://cir.nii.ac.jp/all?q=Retreatment","dc:title":"Retreatment"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Immunologic%20Factors","dc:title":"Immunologic Factors"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Anti-TNF;%20Behc%CC%A7et's%20disease;%20Efficacy;%20Safety;%20Vasculitis","dc:title":"Anti-TNF; Behçet's disease; Efficacy; Safety; Vasculitis"},{"@id":"https://cir.nii.ac.jp/all?q=Anti-TNF;%20Behc%CC%A7et's%20disease;%20Efficacy;%20Safety;%20Vasculitis;%20Adult;%20Antibodies,%20Monoclonal;%20Behcet%20Syndrome;%20Female;%20Humans;%20Immunologic%20Factors;%20Immunosuppressive%20Agents;%20Male;%20Recurrence;%20Retreatment;%20Retrospective%20Studies;%20Severity%20of%20Illness%20Index;%20Treatment%20Outcome;%20Tumor%20Necrosis%20Factor-alpha;%20Immunology;%20Immunology%20and%20Allergy;%20Medicine%20(all)","dc:title":"Anti-TNF; Behçet's disease; Efficacy; Safety; Vasculitis; Adult; Antibodies, Monoclonal; Behcet Syndrome; Female; Humans; Immunologic Factors; Immunosuppressive Agents; Male; Recurrence; Retreatment; Retrospective Studies; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Immunology; Immunology and Allergy; Medicine (all)"},{"@id":"https://cir.nii.ac.jp/all?q=Immunosuppressive%20Agents","dc:title":"Immunosuppressive Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Retrospective%20Studies","dc:title":"Retrospective Studies"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285709150943744","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Behçet Uveitis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643782914688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Treatment of Connective Tissue Disease-Related Intractable Disease with Biological Therapeutics"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757449118336","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy and Safety of Tocilizumab in the Management of Non-Infectious Uveitis Failed with Conventional Immunomodulatory and Anti-TNFα Therapies"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846642691001856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Infliximab therapy for intestinal, neurological, and vascular involvement in Behcet disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1361694365736634880","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Evidence-based diagnosis and clinical practice guidelines for intestinal Behçet’s disease 2020 edited by Intractable Diseases, the Health and Labour Sciences Research Grants"}]},{"@id":"https://cir.nii.ac.jp/crid/1390570543474128640","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"High-dose-infliximab-associated Cerebral Venous Sinus Thrombosis: A Case Report and Review of the Literature"}]},{"@id":"https://cir.nii.ac.jp/crid/1520573330243459584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Evaluation of efficacy of infliximab for retinal vasculitis and extraocular symptoms in Behcet disease"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.jaut.2015.06.005"},{"@type":"OPENAIRE","@value":"doi_dedup___::e3b15c27528227db725d0dc9fc742fb7"},{"@type":"CROSSREF","@value":"10.1007/s10384-018-0589-2_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"},{"@type":"CROSSREF","@value":"10.1080/09273948.2017.1279840_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"},{"@type":"CROSSREF","@value":"10.1097/md.0000000000003863_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"},{"@type":"CROSSREF","@value":"10.2169/internalmedicine.6447-20_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"},{"@type":"CROSSREF","@value":"10.2147/oarrr.s328211_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"},{"@type":"CROSSREF","@value":"10.1080/09273948.2022.2126374_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"},{"@type":"CROSSREF","@value":"10.1007/s00535-020-01690-y_references_DOI_196CQLtcgnu02qt1uJZFOPVQLgJ"}]}